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Background: The diagnosis of pancreatic adenocarcinoma and chronic pancreatitis often
rely on expensive and invasive diagnostic approaches, which are not always discriminative
since patients with chronic pancreatitis and pancreatic adenocarcinoma may present with
similar symptoms. Volatile organic compounds (VOCs) in expired breath, could be used as a
non-invasive diagnostic biological marker for detection of pancreatic pathology. Detection
and discrimination of pancreatic pathology with an electronic nose has not yet been reported.
Purpose: The objective of this pilot study was to determine the diagnostic potential of an
electronic nose to identify pancreatic adenocarcinoma and chronic pancreatitis by analyzing
volatile organic compoundg (VOC) proﬁles in exhaled air.
Patients and methods: In a multicenter study, the exhaled air of 56 chronic pancreatitis
patients, 29 pancreatic adenocarcinoma patients, and 74 disease controls were analyzed using
an electronic nose based on 3 metal oxide sensors (MOS). The measurements were evaluated
utilizing an artiﬁcial neural network.
Results: VOC proﬁles of chronic pancreatitis patients could be discriminated from disease
controls with an accuracy of 0.87 (AUC 0.95, sensitivity 80%, speciﬁcity 92%). Also, VOC
proﬁles of patients with pancreatic adenocarcinoma differed from disease controls with an
accuracy of 0.83 (AUC 0.87, sensitivity 83%, speciﬁcity 82%). Discrimination between
chronic pancreatitis and pancreatic adenocarcinoma showed an accuracy of 0.75 (AUC
0.83, sensitivity 83%, speciﬁcity 71%).
Conclusion: An electronic nose may be a valuable diagnostic tool in diagnosis of pancreatic
adenocarcinoma and chronic pancreatitis. The current study shows the potential of an
electronic nose for discriminating between chronic pancreatitis, pancreatic adenocarcinoma
and healthy controls. The results from this proof-of-concept study warrant external validation
in larger cohorts.
Keywords: pancreatic adenocarcinoma, chronic pancreatitis, electronic nose, exhaled breath
Introduction
Pancreatic adenocarcinoma is the seventh most common cause of cancer-related
deaths worldwide.1 In patients with chronic pancreatitis, the risk of developing
pancreatic carcinoma is increased.2 The majority of patients with pancreatic ade-
nocarcinoma have locally advanced or metastatic disease when diagnosed.
Therefore, diagnosis in an asymptomatic stage could improve prognosis. Also, it
is known that chronic pancreatitis can mimic pancreatic carcinoma.3 Discrimination
between pancreatic adenocarcinoma and chronic pancreatitis is important, since the
two diseases have different treatment strategies and prognoses.
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Volatile organic compounds (VOC) in exhaled breath
could be used as a non-invasive diagnostic biological marker
for detection of pancreatic pathology. Previously, numerous
disorders have been linked to unique breath proﬁles, includ-
ing tuberculosis, lung cancer, asthma and cystic ﬁbrosis, head
and neck cancer and amyotrophic lateral sclerosis.4–8 In
2016, Mayerle and co-workers identiﬁed biomarker signa-
tures which may differentiate between pancreatic adenocar-
cinoma and chronic pancreatitis, showing the potential value
of using metabolic markers.9 Most studies were performed
with a laborious and expensive gas chromatography-mass
spectroscopy (GC-MS) set-up. Analysis of VOC breath pat-
terns using an electronic nose is a promising technology to
discriminate between chronic pancreatitis and pancreatic
adenocarcinoma.
Therefore, we aimed to determine the diagnostic potential
of an electronic nose (Aeonose, The eNose Company, the
Netherlands) to differentiate between individuals with
chronic pancreatitis, pancreas adenocarcinoma and disease
controls based on exhaled air analysis. By using artiﬁcial
neural network (ANN) software, exhaled-breath patterns can
be distinguished.
A detailed description of patient selection and methods is
available in the Methods section.5 Brieﬂy, the diagnostic
accuracy of the electronic nose was examined in a multi-
center, prospective design in 56 participants with chronic
pancreatitis and 29 patients with pancreatic adenocarcinoma.
In patients with chronic pancreatitis, the diagnosis was con-
ﬁrmed in 19 patients by endoscopic ultrasound (EUS)
according to the Rosemont criteria and in 37 patients with
computed tomography (CT)/Magnetic Resonance Imaging
(MRI) only. The diagnosis in patients with pancreatic adeno-
carcinoma was conﬁrmed by histology after surgery in 15
patients, by EUS-FNA in 12 patients and by CT-scan only in
2 patients. These patients were recruited from the outpatient
clinics and clinical wards of the Department of
Gastroenterology & Hepatology and Department of
Surgery, at Medisch Spectrum Twente (MST), University
Medical Centre Groningen (UMCG), and Ziekenhuisgroep
Twente (ZGT), the Netherlands.
For ﬁve minutes, the subjects gently breathed
through a mouthpiece which was attached to the elec-
tronic nose. Baseline characteristics of these groups are
shown in Table 1. The breath proﬁles and classiﬁcations
Table 1 Baseline characteristics of study participants
Chronic pancreatitis Pancreatic adenocarcinoma Controls
Male, n (%) 36 (63%)^ 15 (60%) 29 (40%)
Age, mean ± SD, years 54±10 67±9& 57±15+
BMI, mean ± SD, kg/m2 23.1±3.4^ 25.2±3.4& 25.9±4.6
Current smokinga, n (%) 39 (68%)^ 7 (28%)& 10 (14%)
Regular alcohol intakeb, n (%) 6 (11%) 4 (16%) 5 (7%)
Diabetes Mellitus, n (%) 17 (30%)^ 7 (28%) 2 (3%)+
History of pulmonary diseasec, n (%) 8 (14%) 4 (16%) 7 (10%)
History of malignancy, n (%) 4 (7%) 7 (28%)& 5 (7%)+






Locally resectable 17 (59%)
Locally irresectable 6 (21%)
Metastatic 6 (21%)
Notes: a>5 cigarettes or equivalents per day. b>2 units of alcohol per day. cChronic obstructive pulmonary disease, asthma, usage of inhalers. dTotal serum bilirubin 30 µmol/
L. ^p-value <0.05 for difference between chronic pancreatitis versus controls. +p-value <0.05 for difference between pancreatic adenocarcinoma versus controls. &p-value
<0.05 for difference between chronic pancreatitis versus pancreatic adenocarcinoma.
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were used to train ANN, and subsequently cross-vali-
dated using the “Leave-10%-Out” method.5
Methods
Study design
The study concerns a multicenter, prospective, case-dis-
ease control design in subjects with conﬁrmed diagnosis of
chronic pancreatitis or pancreatic adenocarcinoma. The
study was conducted between April 2015 and July 2017.
Subjects
Patients with chronic pancreatitis (CP), pancreatic adeno-
carcinoma and disease controls were recruited sequentially
during a single visit at the outpatient clinic of Department
of Gastroenterology & Hepatology and Department of
Surgery at Medisch Spectrum Twente (MST), University
Medical Center Groningen (UMCG) and Ziekenhuisgroep
Twente (ZGT), or in the respective clinical wards, all in
the Netherlands.
In patients with chronic pancreatitis, 46 patients were
in remission and 10 were analyzed during an exacerbation.
The disease control group consisted of subjects without
relevant disease states, which were referred for colono-
scopy because of changed bowel habit or rectal bleeding.
They were included as disease controls when colonoscopy
and pathological analysis excluded colorectal cancer or
advanced adenoma. Subjects with (hyperplastic) polyps
as well as non-advanced adenomas were accepted as dis-
ease controls. Individuals with an unclear diagnosis were
excluded from the study. In patients with pancreas cancer,
23 carcinomas were located in the head, 5 in the body and
1 in the tail.
69 subjects were excluded from the analyses, largely
due to other active malignancies, infections, inﬂammations
or inability to provide exhaled air. 6 subjects were
excluded due to technical problems. Exhaled air was ana-
lyzed in 56 subjects with chronic pancreatitis, 29 subjects
with pancreatic adenocarcinoma and 74 disease controls.
Inclusion criteria for the subjects were: age ≥18
years, written informed consent, no breathing pro-
blems. Exclusion criteria were hemodynamic instabil-
ity, severe pulmonary or cardiovascular disease, liver
and/or renal insufﬁciency, unstable diabetes mellitus,
systemic inﬂammatory disease, unstable thyroid func-
tion, oral corticosteroid use, active treatment with
radiotherapy and/or chemotherapy, active primary
malignancy other than pancreatic adenocarcinoma. All
recorded personal information was anonymized, includ-
ing age, gender, body mass index, tobacco and alcohol
history, medication, hyperbilirubinemia (>30 mmol/L),
tumor stage, tumor localization and major comorbid-
ities including DM, diseases of heart, lung, kidneys or
liver, and history of malignancies. Current medication
except prednisolone <10 mg daily was allowed. In
order to prevent systematic errors caused by disturbing
smells, no ﬂowers or vegetables were allowed in the
rooms during breath measurement. During the mea-
surements, none of the patients was receiving any spe-
cial therapy which potentially could affect the results.
No patients were included in the study with predniso-
lone> 10 mg, active treatment by radiotherapy and/or
chemotherapy, hemodynamic instability, severe pul-
monary or cardiovascular disease, liver and/or renal
insufﬁciency, unstable diabetes mellitus, systemic
inﬂammatory disease, unstable thyroid function. Initial
treatment after the measurements in patients with can-
cer was resection in 15 patients, neoadjuvant therapy in
1, palliative chemotherapy in 9 and best supportive
care in 5 patients.
Baseline characteristics
Chronic pancreatitis versus controls: Patients with chronic
pancreatitis were comparable to disease controls concerning
gender, age, structural alcohol intake, history of pulmonary
disease, history of malignancy and hyperbilirubinemia.
Current smokers and subjects with diabetes mellitus were
more frequent in chronic pancreatitis patients (see Table 1).
Pancreatic adenocarcinoma versus controls: Patients
with pancreatic adenocarcinoma were comparable to dis-
ease controls concerning gender, body mass index, current
smokers, structural alcohol intake and history of pulmon-
ary disease. Patients with pancreatic adenocarcinoma were
signiﬁcantly older than disease controls. A history of dia-
betes mellitus, malignancy and hyperbilirubinemia was
also higher in subjects with pancreatic adenocarcinoma,
as shown in Table 1
Chronic pancreatitis versus pancreatic adenocarcinoma:
Patients diagnosed with pancreatic adenocarcinoma were
signiﬁcantly older, had higher BMI, a more frequent history
of malignancy or hyperbilirubinemia than subjects with
chronic pancreatitis. There were no signiﬁcant differences
observed in gender, structural alcohol intake, diabetes mel-
litus and history of pulmonary disease between the two
groups, as seen in Table 1.
Dovepress Uslu et al
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Exhaled-breath collection
To minimize confounding factors, participants were
requested to rest and refrain from food and drinking for
at least three hours prior to the measurement, with the
exception of water. The subjects breathed through a
mouthpiece with a carbon ﬁlter, which was attached to
the electronic nose. Also, a HEPA ﬁlter was mounted in
the mouthpiece to prevent contamination of the inner
structure of the electronic nose. Inhaled air passed through
a carbon ﬁlter; the valve to the Aeonose was then closed.
Exhaled air passed through the bacterial ﬁlter into the
Aeonose; the valve to the outside of the mouthpiece was
then closed. A nose clamp was used to force patients to
breathe through the Aeonose. Patients were requested to
exhale through the electronic nose for 5 mins. During the
study, 3 electronic nose devices were randomly used to
rule out potential inter-device differences.
System descriptions; the electronic nose
The integrated device technology in the current study is
based on an array of three metaloxide sensors attached to a
micro hotplate. The sensors act as semiconductors at differ-
ent temperatures ranging 230–340°C. VOCs in exhaled air
interact with these sensors, resulting in redox reactions chan-
ging the conductivity of the sensors. The response of redox
reactions depends on the surface material of the sensor,
temperature cycle and the gas composition. Different organic
compounds express various responses at different tempera-
tures for the same sensor type. These reactions then result in
changing the conductivity of each sensor surface that can be
recorded as electronic signal and quantiﬁed as unique smell-
print. The information obtained was transferred from the
device to a notebook for assessment. Consequently, the
smell-prints recorded from different samples were arranged
in groups by pattern recognition algorithms.
Pattern recognition and data analysis
A breath proﬁle consists of approx. 7000 data points for
each patient. First, the data are pre-processed (eg, standar-
dized) in order to compensate for deterioration in time of
the sensors. Then the data are compressed using a
Tucker3-like algorithm, as it is too large to analyze. In
this way, redundant data and noise are removed. This data
reduction process does not result in loss of signiﬁcant data.
It turns out that the breath proﬁle can be represented by a
vector with 6–15 elements.5
Together with the classiﬁcation obtained from other
diagnostic techniques, the compressed vectors are used
for training ANN. In this way, the ANN settings for a
speciﬁc disease can be ﬁxed.
In order to check whether the ANN is actually capable
of classifying on the disease and not on some artifact,
“leave-10%-Out“ cross-validation is applied: In this
method, 90% of the dataset is used for training the ANN,
while the remaining 10% is predicted. Next, another 10%
of the dataset is classiﬁed on the remaining 90% used for
training. This process is being repeated 10 times and in
that way, in fact, all patients can be classiﬁed based on a
model from the other measurements. Once an ANN model
has been ﬁxed, unknown vectors representing breath pro-
ﬁles can be classiﬁed without needing the availability of
additional diagnostic information.
During the data analysis, multiple ANNs can be
derived using different sensor combinations (A, B, C,
AB, AC, BC, ABC), pre-processing techniques, vector
lengths and ANN topologies.
The models were all evaluated in terms of sensitiv-
ity and speciﬁcity and ranked in that way. For this
data-analysis process, proprietary software package
Aethena was used. Additionally, IBM SPSS Statistics,
version 22 for Windows (IBM SPSS Statistics, IBM
Corporation, Armonk, NY) was utilized to create recei-
ver operating characteristic (ROC) curves to establish
the area under the curve (AUC). Two-tailed t-tests
were executed to analyze continuous data after evalua-
tion of symmetric distribution in statistics. Chi-square
tests (χ2 test) were used for distributions of categorical
data. Fisher’s exact test was utilized with small sample
sizes.
Results
The electronic nose was able to distinguish between
chronic pancreatitis and disease controls with an accuracy
of 87% (Figure 1A), sensitivity 80% (95% CI: 67–89%),
speciﬁcity 92% (95% CI: 83–96%), negative predictive
value of 86% (95% CI: 76–93%) and a positive predictive
value of 88% (95% CI: 75–95%).
Pancreatic adenocarcinoma was distinguished from dis-
ease controls with an accuracy of 83% (Figure 1B), sensitiv-
ity 83% (95% CI: 64–93%), speciﬁcity 82% (95% CI: 71–
90%), negative predictive value of 92% (95% CI: 82–97%)
and a positive predictive value of 65% (95 CI: 47–79%).
Uslu et al Dovepress
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The electronic nose discriminated pancreatic adenocarci-
noma from chronic pancreatitis with an accuracy of 75%
(Figure 1C), sensitivity 83% (95% CI: 64–93%), speciﬁcity
71% (95% CI: 58–82%), negative predictive value of 89%
(95% CI: 75–96%) and a positive predictive value of 60%
(95% CI: 43% 75%).
Discussion
Our study has a number of limitations. Firstly, it is unclear
which VOCs are responsible for detection of pancreatic
pathology by an electronic nose. Secondly, detection of
pancreatic adenocarcinoma may be stage-dependent. Thus,
it remains unknown whether early pancreatic cancer could
be detected as well. Also, localization of the lesion may
effect metabolism, which in turn may effect VOC patterns.
Although the disease control group was not screened for
pancreatic pathology, disease controls were assumed not to
suffer from pancreatic pathology, considering its low inci-
dence. Furthermore, various patients with adenocarcinoma
were cholestatic. Cholestasis may have profound effects
on metabolism, and therefore on exhaled VOCs. In chronic
pancreatitis patients, exacerbation of complaints may also
affect metabolism, and therefore exhaled VOCs. Finally,
smoking habits and/or alcohol intake may have affected
our ﬁndings.
Our results suggest that chronic pancreatitis patients,
pancreatic adenocarcinoma patients and disease controls
exhibit differences in metabolism reﬂected by differences
in measured VOC patterns. The current study reﬂects the
potential of an electronic nose for detecting chronic pan-
creatitis and pancreatic adenocarcinoma. The major
advantage of the Aeonose is that it allows for easy
measurement within minutes, in contrast to the laborious
standard VOC-techniques using gas chromatography. The
classiﬁcation of VOC patterns by extensive neural net-
work modeling may improve with a larger number of
subjects. With increased sensitivity and speciﬁcity, the
Aeonose may be a useful tool in the workup of patients
with suspected pancreatic disease. It may also have a role
in non-invasive screening of high-risk subjects, or follow-
up after pancreatic surgery for pancreatic adenocarci-
noma. The results in our study need validation in a larger
multicenter blinded cohort with pre-diagnosed subjects,
stratiﬁed for cholestasis, localization, stage and exacerba-
tion, in line with STARD Statement.10
Ethical considerations
The current study was authorized by the local medical ethics
committee, Medische Ethische Toetsingscommussie (METC)





































































Figure 1 (A) ROC curve in chronic pancreatitis versus healthy controls; (B) ROC curve in pancreatic adenocarcinoma versus controls; and (C) ROC curve in chronic
pancreatitis versus pancreatic adenocarcinoma.
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the Helsinki Declaration. All patients were informed both
verbally and on paper, and they had given their written
informed consent before taking part in measurements. The
staff of participating hospitals received written information
and they were orally informed fully about the study.
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